iVascular
iVascular is a Barcelona-based, privately held medical device company founded in 2010 that designs and manufactures vertically integrated drug-eluting stents, drug-coated balloons and catheters for coronary, peripheral and neurovascular interventions, sold to tertiary hospitals and specialist physicians across Europe, Asia and Latin America.
- Company typePrivate
- Founded2010
- HeadquartersBarcelona, Spain
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What iVascular does
iVascular, S.L.U. is a Barcelona-based, founder-led medical device company founded in 2010 that designs, manufactures and commercializes catheter-based cardiovascular devices — drug-eluting stents (DES), drug-coated balloons (DCB), support catheters, microcatheters, aspiration catheters and stent retrievers — for coronary, peripheral and neurovascular indications. All products are produced at its vertically integrated Sant Vicenç dels Horts facility ('100% Made in Europe'), with the company's competitive differentiation resting on proprietary nanocoatings and encapsulation chemistries: TransferTech (Luminor DCB), TransferWise (Angiolite DES), CoverTech (iCover covered stent) and Hydrax Plus (neuro catheters). The portfolio spans 18+ commercialized SKUs across three therapeutic areas, supplemented by a clinical pipeline that includes the OPAL first-in-human study of the Amber radiopaque embolic liquid.
The company operates a hybrid go-to-market model: direct enterprise field sales to interventional cardiologists, vascular surgeons, interventional radiologists and tertiary hospitals, complemented by country-specific distribution partnerships (e.g., Medico's Hirata in Japan) and clinical-evidenced demand generation via a portfolio of 12+ registered trials and proprietary medical congresses (iVS Barcelona, Latam, Osaka). Reimbursement has been secured for Luminor DCB in France (2019) and Angiolite DES in Belgium (2020), with regulatory approvals across the EU, Japan (MHLW, 2025), India (2017), and broader Latin America. Physician engagement is reinforced by the iCardio Grant, iVascular Grant and UAB Research Chair programs.
Revenue mechanics are quote-based hardware sales to hospitals, healthcare systems and distributors; pricing is not publicly disclosed. Notable customers are tertiary and academic centers (Hospital Clinic Barcelona, Hospital La Fe, Kokura Memorial, ICBA Buenos Aires, University Hospital Jena), which function both as commercial reference sites and as Principal Investigator sites for the company's evidence-generation engine. The company is privately held with 51–100 employees and no disclosed funding rounds, suggesting bootstrapped or self-financed growth to date.
iVascular firmographics
Firmographics- Name
- iVascular
- Legal name
- iVascular, S.L.U.
- Website
- https://ivascular.global
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- iVascular is a Barcelona-based, privately held medical device company founded in 2010 that designs and manufactures vertically integrated drug-eluting stents, drug-coated balloons and catheters for coronary, peripheral and neurovascular interventions, sold to tertiary hospitals and specialist physicians across Europe, Asia and Latin America.
- Ownership category
- akta.pro rank
Where iVascular is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
iVascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical device sales: iVascular generates revenue primarily through one-time sales of its cardiovascular medical devices (drug-eluting stents, drug-coated balloons, and catheters) to hospitals, healthcare systems, and distributors. Sales are made directly via a sales force and indirectly via distribution partners such as Medico's Hirata in Japan.
- Reimbursed product sales (Europe): iVascular's Luminor DCB and Angiolite DES have achieved reimbursement in multiple European countries including France (Luminor DCB since 2019) and Belgium (Angiolite DES since 2020), enabling recurring institutional revenue from hospital purchasers.
Go-to-market motion4 records
Distribution channels3 records
Marketing channels6 records
iVascular product offering
Product offeringCore offering
iVascular designs, develops and manufactures catheter-based cardiovascular medical devices—including drug-eluting stents (DES), drug-coated balloons (DCB) and microcatheters/aspiration catheters—for the endovascular treatment of coronary, peripheral and neurovascular disease, all produced at its vertically integrated "100% Made in Europe" facility in Barcelona, Spain. Its portfolio is organized across three therapeutic areas (Coronary, Peripheral, Neurointerventionism) and is differentiated by proprietary nanocoating and encapsulation technologies (TransferTech, TransferWise, CoverTech, Hydrax Plus). The company sells these devices to hospitals and physicians through direct enterprise sales and regional distribution partners, supported by an active clinical-trial program (12+ registered trials) and physician education initiatives such as the Interactive Vascular Summit (iVS).
Product overview
iVascular, S.L.U. is a Barcelona-based medical device company (100% Made in Europe) offering a vertically integrated portfolio of catheter-based, drug-eluting, and coated devices for the endovascular treatment of vascular disease. Its offering is organized as a platform-plus-modules architecture along three therapeutic areas — Coronary (Angiolite DES, Angiolite BTK DES, Essential pro DCB, Capturer, Naviscore, Navitian microcatheter, NC xperience, Xperience pro), Peripheral (Luminor DCB in 14/18/35 platforms, iVolution pro nitinol stent, iCover covered stent, Oceanus, Restorer, Sergeant support catheter), and Neurointerventionism (iNedit distal-access balloon catheter, iNdeep microcatheter family, iNtercept stent retriever, iNstroke 4F and 6F aspiration catheters). Cross-cutting proprietary technologies — TransferTech and TransferWise nanocoatings, CoverTech encapsulation, and Hydrax Plus hydrophilic coating — differentiate the device families, while the pipeline includes the Amber radiopaque embolic liquid (in OPAL first-in-human study). The portfolio is supported by education programs including the iCardio Grant, iVascular Grant, and the interactive Vascular Summit (iVS) congress series.
Differentiator
Problem solved
Functional benefit
Brands
- Angiolite: Sirolimus-eluting coronary stent (DES) for treating stenotic and restenotic coronary lesions; Angiolite BTK variant for below-the-knee procedures.
- Luminor
- essential pro
- iVolution pro
- iCover
- Oceanus
- Sergeant
- Restorer
- Navitian
- Naviscore
- Capturer
- NC Xperience
- Xperience pro
- Angiolite BTK
- iNedit
- iNdeep
- iNtercept
- iNstroke 4F
- iNstroke 6F
- Amber
Products and services
- Angiolite (coronary) Sirolimus-eluting cobalt-chromium coronary stent on a rapid-exchange platform with iVascular's proprietary TransferWise fluoropolymer nanocoating and alternating links for homogeneous arterial coverage and high endothelization rates; indicated for stenotic, restenotic and occlusive lesions in coronary arteries, with 44 and 49 mm lengths available for diffuse disease.
- Angiolite BTK Sirolimus-eluting stent variant of Angiolite designed for below-the-knee (BTK) peripheral procedures, with safety and feasibility in BTK interventions demonstrated in the ANGIOLITE BTK Trial.
- Essential pro Paclitaxel drug-coated balloon for coronary applications including in-stent restenosis (ISR) and small vessels, demonstrating high deliverability, low target-lesion revascularization and minimal adverse events in clinical studies.
- iCover Balloon-expandable covered stent for renal and iliac arteries, aneurysms and ruptures, encapsulating ePTFE layers via iVascular's patented CoverTech technology; features tantalum radiopaque markers and high flexibility for tortuous vessels.
- iVolution pro
Quantifiable outcome
- 94.9% primary patency at 12 months in SOL Japan trial of Luminor DCB
- +6 more outcomes
Companies that use iVascular
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles3 records
iVascular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
iVascular partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- iCardio Grant Scientific CommitteecoreScientific Committee of KOLs who evaluate cases for the iCardio Grant competition: Dr. Roberto Garbo (Maria Pia Hospital, GVM Turin), Dr. Maciej Lesiak (Poznan University of Medical Sciences), Dr. Kambis Mashayekhi (MediClin Herzzentrum Lahr), Dr. Soledad Ojeda (Hospital Reina Sofía, Córdoba), Dr. Antoni Serra (Hospital Sant Pau i Santa Creu, Barcelona).
- Hospital La Fe, Valencia (Dr. Fernando Gomez)coreDr. Fernando Gomez leads the OPAL study of iVascular's new embolic liquid Amber in collaboration with 10 Spanish centers specialized in embolization. The study enrolls 70 patients requiring peripheral embolization across indications including vascular anomalies, hemorrhages, aneurysms, pseudoaneurysms, type II endoleaks, varicose veins, portal veins, hypervascular tumors, and pathological organs.
- Universitat Autònoma de Barcelona (UAB)flagshipiVascular established the Research Chair in Surgery at the UAB Faculty of Medicine led by Prof. José María Balibrea. Activities include studies in robotic surgery and an international training course on innovation and value creation in surgical research, culminating in the 'School of Innovation in Surgery.' Dean Prof. Salvador Navarro Soto endorsed the public-private alliance.
- Hospital Clinic Barcelona (Dr. Manel Sabaté)coreDr. Manel Sabaté (Head of Interventional Cardiology at Hospital Clinic Barcelona) is the Principal Investigator of the ANGIODAPT trial, a 2x2 factorial, all-comer, multicenter RCT evaluating abbreviated DAPT post-Angiolite DES implantation. The trial involves 2,312 patients across 40 sites in Spain, Belgium and France with 5-year follow-up. Steering committee includes Dr. Rodés, Dr. Brugaletta, Dr. Ortega, Dr. Dewilde and Dr. Garot.
- Universitat Autònoma de Barcelona - Research Chair in SurgeryflagshipStrategic research collaboration to advance innovation in surgery, including robotic surgery studies and creation of the 'School of Innovation in Surgery' to train healthcare professionals with global figures in research.
- Medico's HirataflagshipiVascular partners with Medico's Hirata, a Japanese medical device company, to distribute Luminor DCB in Japan. The alliance began with the SOL-Japan clinical trial (April 2021) and culminated in Luminor DCB receiving MHLW approval (May 2025), with a Japan-specific Luminor 18 RX version developed for the Japanese market. The partnership represents a strategic entry into Japan (~1.7% of world population).
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
iVascular competitors and assessment
Company assessmentDirect peers
- Meril Life Sciences: Indian privately held medical device company with coronary (Metafor sirolimus DES) and peripheral (Praza DCB) franchises, comparable vertically integrated manufacturing model and similar scale, competing in many of the same emerging markets as iVascular.
- MicroPort Scientific: Chinese-headquartered medical device group with coronary DES (Firehawk, Firebird) and peripheral DCB/stent franchises; comparable vertically integrated business model and product breadth across coronary and peripheral vascular indications.
- Penumbra: US-based neurovascular and peripheral thrombectomy specialist whose aspiration catheters and stent retrievers directly overlap with iVascular's iNstroke and iNtercept neurointervention portfolio, addressing the same acute ischemic stroke call points.
- BIOTRONIK: Privately held German manufacturer of coronary stents (Orsiro), peripheral devices and electrophysiology implants, with a similar vertically integrated European manufacturing footprint and comparable mid-cap scale and product breadth across vascular indications.
- Acotec Scientific: Chinese DCB-focused medical device company whose peripheral (Orchid) and coronary drug-coated balloons directly compete with iVascular's Luminor and Essential pro franchises, with similar mid-cap scale and emerging global expansion.
Broad incumbents
- Cordis: Independent (post-Cardinal Health spinout) global interventional cardiovascular business offering stents, DCBs and catheters; overlaps with iVascular's coronary and peripheral portfolios and competes for the same hospital procurement budgets, but at significantly larger scale.
- Terumo: Japanese global medical device incumbent with a substantial interventional systems division (peripheral and coronary DCBs, stents and access devices) that competes with iVascular in peripheral intervention and is a logical Japanese-market competitor following iVascular's Luminor launch in Japan.
- Stryker (Neurovascular): Through its Neurovascular division (Trevo, AXS), Stryker competes directly with iVascular's iNstroke aspiration catheters, iNtercept stent retriever and iNdeep microcatheters in the acute ischemic stroke market, with substantially larger sales and clinical evidence resources.
Regional players
- Balton: Polish interventional cardiology and peripheral device manufacturer with a similar mid-cap profile and European focus; competes with iVascular primarily in Central and Eastern European hospital tenders rather than globally.
Emerging players
- Surmodics: US-based medical device coating and drug-delivery company whose proprietary hydrophilic and drug-coating technologies overlap with iVascular's TransferTech and Hydrax Plus platforms, and which supplies/sells into the peripheral DCB ecosystem where iVascular competes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
iVascular social profiles
Digital presenceiVascular compliance and trust
Trust signalCompliance8 records
iVascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
iVascular leadership team
Management profileNumber of profiles
Profiles2 records
iVascular funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iVascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iVascular
What does iVascular do?
iVascular designs, develops and manufactures catheter-based cardiovascular medical devices—including drug-eluting stents (DES), drug-coated balloons (DCB) and microcatheters/aspiration catheters—for the endovascular treatment of coronary, peripheral and neurovascular disease, all produced at its vertically integrated "100% Made in Europe" facility in Barcelona, Spain. Its portfolio is organized across three therapeutic areas (Coronary, Peripheral, Neurointerventionism) and is differentiated by proprietary nanocoating and encapsulation technologies (TransferTech, TransferWise, CoverTech, Hydrax Plus). The company sells these devices to hospitals and physicians through direct enterprise sales and regional distribution partners, supported by an active clinical-trial program (12+ registered trials) and physician education initiatives such as the Interactive Vascular Summit (iVS).
Is iVascular a public or private company?
iVascular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was iVascular founded?
iVascular was founded in 2010. It employs 51 to 100 people.
Where is iVascular based?
iVascular is headquartered in Barcelona, Spain, in the Europe region.
How does iVascular make money?
Two revenue lines are on record. Medical device sales are the primary driver. The others are reimbursed product sales (Europe).
Who are iVascular's main competitors?
Direct peers on record are Meril Life Sciences, MicroPort Scientific, Penumbra, BIOTRONIK and Acotec Scientific. Broad incumbents are Cordis, Terumo and Stryker (Neurovascular). Balton is listed as a regional player. Surmodics is listed as an emerging player.
Does iVascular have an API?
No public API is recorded for iVascular.